The 14th Huntington’s Disease Therapeutics Conference provided a forum to review the significant progress in HD clinical development, learn about exciting new findings, and build a collaborative path forward to overcome the remaining challenges to accelerating the development of therapeutics that will substantially benefit HD families.
ViewFeaturing pharma R&D leaders, innovators on the cutting edge of technology, and visionaries that are shaping the future of healthcare.
ViewHAI 2019 will emphasize lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily spring from brief presentations by active investigators who will report on unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.
View153-155 of 155 results